CBD and CBG May Reverse Fatty Liver Disease, Study Finds

A Condition Without a Cure Meets Cannabis Science

Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease—is the most widespread chronic liver condition on the planet. It affects roughly one-third of adults globally, is strongly associated with obesity, high blood pressure, and insulin resistance, and until now has had no approved pharmaceutical treatment.

That may be about to change, thanks to two non-psychoactive cannabinoids: CBD (cannabidiol) and CBG (cannabigerol).

A groundbreaking study published in the British Journal of Pharmacology in early 2026, conducted by researchers at the Hebrew University of Jerusalem, found that both CBD and CBG could help treat fatty liver disease through two previously unknown mechanisms—giving the liver a backup energy source and restoring its cellular cleanup systems.

How the Study Worked

The research team, led by scientists at Hebrew University's Institute for Drug Research, used animal models fed high-fat diets to simulate the metabolic stress that causes fatty liver disease in humans. They then administered CBD and CBG separately to examine how each compound affected liver function, fat accumulation, and metabolic markers.

What they found surprised even the researchers. Rather than simply reducing inflammation—the mechanism most commonly associated with cannabinoid therapeutics—CBD and CBG appeared to address the root causes of fatty liver through entirely different pathways.

The Two Key Mechanisms

Phosphocreatine Buffering: A Backup Battery for Your Liver

The first mechanism involves phosphocreatine, a molecule that acts like a rapid-response energy reserve in cells. When the liver is stressed by excess fat—as happens in MASLD—its normal energy production pathways become overwhelmed.

CBD and CBG were found to increase phosphocreatine levels in liver cells, essentially providing a "backup battery" that helps the organ maintain healthy function even under the metabolic stress caused by a high-fat diet. This energy buffering prevents the cascade of cellular damage that typically leads to liver fibrosis and eventually cirrhosis.

Lysosomal Restoration: Rebooting the Cell's Cleanup Crew

The second mechanism is equally fascinating. Lysosomes are organelles that function as a cell's recycling center—they break down waste products, damaged proteins, and excess fats. In fatty liver disease, lysosomal function becomes impaired, allowing harmful fats and cellular waste to accumulate.

CBD and CBG were shown to restore the activity of cathepsins—enzymes within lysosomes that act as the molecular cleaning crew. By rebooting this cellular cleanup system, the cannabinoids helped liver cells clear out the accumulated fats and damaged materials that drive disease progression.

CBG Showed an Edge

While both cannabinoids demonstrated therapeutic potential, CBG appeared to be the stronger performer in several categories. The study found CBG was more effective at reducing overall body fat and increasing insulin sensitivity—both critical factors in managing MASLD.

This finding is particularly significant because CBG has historically been overshadowed by CBD in both research and consumer markets. As the "mother cannabinoid" from which other cannabinoids are synthesized in the plant, CBG is present in much lower concentrations in most cannabis strains, making it more expensive to produce. However, advances in breeding and extraction technology have made CBG products increasingly accessible in recent years.

Beyond the Liver: Metabolic Benefits

The study's findings extended beyond liver health alone. Both CBD and CBG improved blood sugar control and reduced harmful lipids associated with fatty liver disease. These systemic metabolic improvements suggest that cannabinoid therapy could address the broader metabolic syndrome that typically accompanies MASLD—including insulin resistance, dyslipidemia, and chronic low-grade inflammation.

The researchers noted that these metabolic benefits occurred without the psychoactive effects associated with THC, making CBD and CBG potentially suitable for chronic daily use as therapeutic agents.

What This Means for Patients

It's important to note that this research was conducted in animal models, and human clinical trials are needed before any therapeutic claims can be made. However, the findings are significant for several reasons.

First, MASLD currently has no approved drug treatment. The only recommended interventions are lifestyle changes—weight loss, exercise, and dietary modification. For the estimated 1.5 billion people worldwide living with some form of fatty liver disease, effective pharmaceutical options are desperately needed.

Second, CBD is already widely available as a consumer supplement in most markets, and CBG is increasingly accessible. While current over-the-counter products may not deliver the specific doses used in the study, the existence of an established supply chain could accelerate the path from research to clinical application.

Third, the safety profile of CBD and CBG is well-established through years of consumer use and clinical research. Unlike many experimental liver therapeutics, these compounds carry relatively low risk of serious adverse effects.

The Broader Research Landscape

This study adds to a remarkable body of cannabinoid research published in early 2026. Over 70 cannabis-related studies have been published this year alone, highlighting the diverse medical potential of cannabis compounds across conditions from cancer to chronic pain to mental health disorders.

The timing is particularly relevant given the Trump administration's April 23 reclassification of medical marijuana to Schedule III, which removes significant barriers to cannabis research. Scientists who previously needed expensive and time-consuming Schedule I licenses can now study cannabinoids with far fewer regulatory hurdles.

Looking Ahead

The Hebrew University team has indicated plans for follow-up studies examining optimal dosing, long-term safety, and potential interactions with existing liver medications. The pathway from preclinical research to clinical trials typically takes several years, but the urgency of the MASLD epidemic—combined with the established safety profiles of CBD and CBG—could accelerate the timeline.

For now, the message is cautiously optimistic: two of the cannabis plant's most accessible, non-psychoactive compounds may hold the key to treating one of the world's most common chronic diseases. That's a finding worth watching closely.

To find CBG- and CBD-forward products on a regulated shelf, Budpedia's cannabis dispensary directory lists 7,400+ verified retailers across every legal state, with current menus and minor-cannabinoid filters where available.